To mark the launch of the Quantidex® QPCR BCR-ABL IS Kit, manufacturer Asuragen held a series of three webinars that examine the evolving clinical landscape around CML, as well as the history of the management of the disease, and what’s coming up in future.
QuantideX BCR-ABL IS Kit provides labs with a robust and reliable method for monitoring leukaemia patients, also allowing them to keep pace with the advances in TKI therapy.
It is seen as a major breakthrough for labs dealing with the monitoring of leukaemia patients, offering reduced complexity and optimised workflow without losing high-quality performance.
You can read about the QuantideX® qPCR BCR-ABL Portfolio in more detail here – but we would strongly recommend listening to/watching the fascinating webinars, too, which are delivered by some of the world’s leading figures in oncology and haematology research and product development.
The first of three webinars is delivered by Prof. Dr. Med. Martin Müller, CEO at the Institute for Haematology and Oncology (IHO GmbH). It focuses on:
- A brief history of CML patient care and the emergence of new and improved treatments
- New frontiers in patient management and the promise of treatment-free remission
- Implications for laboratories conducting BCR-ABL testing
To view the webinar, please click the below image (opens in a new tab):
For more information about the QuantideX® qPCR BCR-ABL Portfolio, contact VH Bio today.